Planegg/Martinsried, February 3, 2025. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell ...
Hosted on MSN1mon
Medigene AG Advances with Equity Agreement to Boost CapitalMedigene ( (DE:MDG1)) has issued an update. Medigene AG has announced the execution of the first tranche of a Standby Equity Purchase Agreement with Yorkville Advisors Global, LP. This move will ...
Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to ...
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today ...
Martinsried, Germany and Montréal, Canada (pta008/02.12.2021/07:30 UTC+1) Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical-stage immuno-oncology company focusing on the development ...
Medigene continuously strengthens and expands its patent portfolio by developing new 3S TCRs, integrating advanced technologies, and extending its existing patents to new regions. The Company now ...
EpimAb_LogoPlanegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback